Hoge Stephen sold $2.7M of MRNA

Moderna (MRNA) shares rose 4.5% as investors await detailed results from a Phase 3 cancer trial with Merck (MRK). The trial, involving 1,137 patients, showed the treatment reduced cancer recurrence. Results will be presented on October 24. Moderna reported a Q2 net loss of $782 million. Barclays estimates potential $3 billion annual melanoma sales by 2035, split equally with Merck.

Moderna (MRNA) shares rose 38% since late September ahead of a presentation on late-stage trial data for its cancer vaccine, developed with Merck (MRK). The rally follows a 170% surge after positive Phase 3 melanoma trial results in August. Moderna's P/S ratio is 41.76, significantly higher than its historical median of 8.48, reflecting market growth expectations despite its unprofitability. Insider activity shows no purchases and $64.6M in sales over the past year.

Moderna's stock rose 658.2% year-to-date, reaching $223.60 premarket. The surge followed positive late-stage trial results for its cancer vaccine, developed with Merck. Analysts' price targets are below current levels, with a consensus at $122.67. Moderna reports Q3 earnings on November 6, with revenue and cash flow expectations to be revealed. The stock trades at 38.75 times trailing sales, raising valuation concerns.

Goldman Sachs maintained a Neutral rating on Moderna (MRNA) but raised its price target to $137 from $120. GuruFocus values MRNA at $23.84, suggesting it is 849.2% overvalued. The company has a GF Score of 54/100, with strengths in financial stability but weaknesses in profitability and valuation. Insider selling totaled $49.18M over the past three months.

Goldman Sachs raised its price target for Moderna (MRNA) to $137 from $120, maintaining a Neutral rating. The firm cited upcoming Phase 3 results for melanoma and Phase 1 data for pancreatic cancer as key catalysts. TipRanks identified three Vanguard ETFs (VO, VNQ, VBR) with potential upside, based on analyst consensus and price targets.

Moderna Inc. (MRNA) shares rose 4.13% on October 14, 2026, driven by optimism around its mRNA cancer vaccine pipeline and inclusion in the Nasdaq-100 Index. The company reported $143M in revenue and a net loss of $782M for the latest quarter, with $5.1B in cash reserves. Analysts have adjusted price targets, with Bank of America raising its target to $200 and Morgan Stanley to $95, both maintaining cautious ratings. The next key catalyst is Moderna's Q3 2026 earnings report on November 6, 2026.